<?xml version='1.0' encoding='utf-8'?>
<document id="22422635"><sentence text="Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes." /><sentence text="To investigate potential drug-drug interactions between clobazam and cytochrome P450 (CYP) isoenzyme substrates, inhibitors, and inducers" /><sentence text="" /><sentence text="Two, prospective, open-label, single-center, drug-drug interaction (DDI) studies and a population pharmacokinetics analysis of seven multicenter phase II-III trials" /><sentence text="" /><sentence text="Clinical research unit" /><sentence text="" /><sentence text="Fifty-four healthy adult volunteers were enrolled in the two drug-drug interaction studies; 53 completed the studies" /><sentence text=" The population pharmacokinetics analysis evaluated data from 171 participants from five studies with healthy volunteers and two studies with patients with Lennox-Gastaut syndrome" /><sentence text=" Participants in these studies received clobazam and stable dosages of the following antiepileptic drugs: phenobarbital, phenytoin, carbamazepine, valproic acid, lamotrigine, felbamate, or oxcarbazepine"><entity charOffset="106-119" id="DDI-PubMed.22422635.s10.e0" text="phenobarbital" /><entity charOffset="121-130" id="DDI-PubMed.22422635.s10.e1" text="phenytoin" /><entity charOffset="132-145" id="DDI-PubMed.22422635.s10.e2" text="carbamazepine" /><entity charOffset="147-160" id="DDI-PubMed.22422635.s10.e3" text="valproic acid" /><entity charOffset="162-173" id="DDI-PubMed.22422635.s10.e4" text="lamotrigine" /><entity charOffset="175-184" id="DDI-PubMed.22422635.s10.e5" text="felbamate" /><entity charOffset="189-202" id="DDI-PubMed.22422635.s10.e6" text="oxcarbazepine" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e0" e2="DDI-PubMed.22422635.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e0" e2="DDI-PubMed.22422635.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e0" e2="DDI-PubMed.22422635.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e0" e2="DDI-PubMed.22422635.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e0" e2="DDI-PubMed.22422635.s10.e4" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e0" e2="DDI-PubMed.22422635.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e0" e2="DDI-PubMed.22422635.s10.e6" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e1" e2="DDI-PubMed.22422635.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e1" e2="DDI-PubMed.22422635.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e1" e2="DDI-PubMed.22422635.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e1" e2="DDI-PubMed.22422635.s10.e4" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e1" e2="DDI-PubMed.22422635.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e1" e2="DDI-PubMed.22422635.s10.e6" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e2" e2="DDI-PubMed.22422635.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e2" e2="DDI-PubMed.22422635.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e2" e2="DDI-PubMed.22422635.s10.e4" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e2" e2="DDI-PubMed.22422635.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e2" e2="DDI-PubMed.22422635.s10.e6" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e3" e2="DDI-PubMed.22422635.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e3" e2="DDI-PubMed.22422635.s10.e4" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e3" e2="DDI-PubMed.22422635.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e3" e2="DDI-PubMed.22422635.s10.e6" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e4" e2="DDI-PubMed.22422635.s10.e4" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e4" e2="DDI-PubMed.22422635.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e4" e2="DDI-PubMed.22422635.s10.e6" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e5" e2="DDI-PubMed.22422635.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22422635.s10.e5" e2="DDI-PubMed.22422635.s10.e6" /></sentence><sentence text="" /><sentence text="In the first drug-drug interaction study, 36 participants received a single oral dose of clobazam 10 mg on day 1, followed by either ketoconazole 400 mg once/day or omeprazole 40 mg once/day on days 17-22, with a single dose of clobazam 10 mg coadministered on day 22, to study the effects of CYP3A4 or CYP2C19 inhibition, respectively, on clobazam and its active metabolite N-desmethylclobazam (N-CLB)"><entity charOffset="89-97" id="DDI-PubMed.22422635.s12.e0" text="clobazam" /><entity charOffset="133-145" id="DDI-PubMed.22422635.s12.e1" text="ketoconazole" /><entity charOffset="165-175" id="DDI-PubMed.22422635.s12.e2" text="omeprazole" /><entity charOffset="228-236" id="DDI-PubMed.22422635.s12.e3" text="clobazam" /><entity charOffset="375-394" id="DDI-PubMed.22422635.s12.e4" text="N-desmethylclobazam" /><entity charOffset="396-401" id="DDI-PubMed.22422635.s12.e5" text="N-CLB" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e0" e2="DDI-PubMed.22422635.s12.e0" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e0" e2="DDI-PubMed.22422635.s12.e1" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e0" e2="DDI-PubMed.22422635.s12.e2" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e0" e2="DDI-PubMed.22422635.s12.e3" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e0" e2="DDI-PubMed.22422635.s12.e4" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e0" e2="DDI-PubMed.22422635.s12.e5" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e1" e2="DDI-PubMed.22422635.s12.e1" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e1" e2="DDI-PubMed.22422635.s12.e2" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e1" e2="DDI-PubMed.22422635.s12.e3" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e1" e2="DDI-PubMed.22422635.s12.e4" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e1" e2="DDI-PubMed.22422635.s12.e5" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e2" e2="DDI-PubMed.22422635.s12.e2" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e2" e2="DDI-PubMed.22422635.s12.e3" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e2" e2="DDI-PubMed.22422635.s12.e4" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e2" e2="DDI-PubMed.22422635.s12.e5" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e3" e2="DDI-PubMed.22422635.s12.e3" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e3" e2="DDI-PubMed.22422635.s12.e4" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e3" e2="DDI-PubMed.22422635.s12.e5" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e4" e2="DDI-PubMed.22422635.s12.e4" /><pair ddi="false" e1="DDI-PubMed.22422635.s12.e4" e2="DDI-PubMed.22422635.s12.e5" /></sentence><sentence text=" In the second study, 18 participants received a drug cocktail consisting of caffeine 200 mg, tolbutamide 500 mg, dextromethorphan 30 mg, and midazolam 4 mg on days 1 and 19, and clobazam 40 mg/day on days 4-19, to study clobazam's effects on CYP1A2, CYP2C9, CYP2D6, and CYP3A4"><entity charOffset="77-85" id="DDI-PubMed.22422635.s13.e0" text="caffeine" /><entity charOffset="94-105" id="DDI-PubMed.22422635.s13.e1" text="tolbutamide" /><entity charOffset="114-130" id="DDI-PubMed.22422635.s13.e2" text="dextromethorphan" /><entity charOffset="142-151" id="DDI-PubMed.22422635.s13.e3" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.22422635.s13.e0" e2="DDI-PubMed.22422635.s13.e0" /><pair ddi="false" e1="DDI-PubMed.22422635.s13.e0" e2="DDI-PubMed.22422635.s13.e1" /><pair ddi="false" e1="DDI-PubMed.22422635.s13.e0" e2="DDI-PubMed.22422635.s13.e2" /><pair ddi="false" e1="DDI-PubMed.22422635.s13.e0" e2="DDI-PubMed.22422635.s13.e3" /><pair ddi="false" e1="DDI-PubMed.22422635.s13.e1" e2="DDI-PubMed.22422635.s13.e1" /><pair ddi="false" e1="DDI-PubMed.22422635.s13.e1" e2="DDI-PubMed.22422635.s13.e2" /><pair ddi="false" e1="DDI-PubMed.22422635.s13.e1" e2="DDI-PubMed.22422635.s13.e3" /><pair ddi="false" e1="DDI-PubMed.22422635.s13.e2" e2="DDI-PubMed.22422635.s13.e2" /><pair ddi="false" e1="DDI-PubMed.22422635.s13.e2" e2="DDI-PubMed.22422635.s13.e3" /></sentence><sentence text="" /><sentence text="In the first DDI study, coadministration of ketoconazole (a CYP3A4 inhibitor) and clobazam increased clobazam's area under the concentration time curve from time zero extrapolated to infinity (AUC(0-∞) ) 54% and decreased clobazam's maximum plasma concentration (C(max) ) by 15% versus administration of clobazam alone, but the combination affected these pharmacokinetic parameters for N-CLB to a lesser degree"><entity charOffset="44-56" id="DDI-PubMed.22422635.s15.e0" text="ketoconazole" /><entity charOffset="386-391" id="DDI-PubMed.22422635.s15.e1" text="N-CLB" /><pair ddi="false" e1="DDI-PubMed.22422635.s15.e0" e2="DDI-PubMed.22422635.s15.e0" /><pair ddi="false" e1="DDI-PubMed.22422635.s15.e0" e2="DDI-PubMed.22422635.s15.e1" /></sentence><sentence text=" The CYP2C19 inhibitor omeprazole increased AUC(0-∞)  and C(max)  of N-CLB by 36% and 15%, respectively, but did not significantly affect the pharmacokinetics of clobazam"><entity charOffset="23-33" id="DDI-PubMed.22422635.s16.e0" text="omeprazole" /><entity charOffset="69-78" id="DDI-PubMed.22422635.s16.e1" text="N-CLB" /><pair ddi="false" e1="DDI-PubMed.22422635.s16.e0" e2="DDI-PubMed.22422635.s16.e0" /><pair ddi="false" e1="DDI-PubMed.22422635.s16.e0" e2="DDI-PubMed.22422635.s16.e1" /></sentence><sentence text=" At steady state, N-CLB has 3-4 times greater exposure than clobazam"><entity charOffset="18-23" id="DDI-PubMed.22422635.s17.e0" text="N-CLB" /><entity charOffset="60-68" id="DDI-PubMed.22422635.s17.e1" text="clobazam" /><pair ddi="false" e1="DDI-PubMed.22422635.s17.e0" e2="DDI-PubMed.22422635.s17.e0" /><pair ddi="false" e1="DDI-PubMed.22422635.s17.e0" e2="DDI-PubMed.22422635.s17.e1" /></sentence><sentence text=" In the second DDI study, no clinically significant drug-drug interactions were observed between clobazam 40 mg and the CYP probe substrates caffeine or tolbutamide"><entity charOffset="141-149" id="DDI-PubMed.22422635.s18.e0" text="caffeine" /><entity charOffset="153-164" id="DDI-PubMed.22422635.s18.e1" text="tolbutamide" /><pair ddi="false" e1="DDI-PubMed.22422635.s18.e0" e2="DDI-PubMed.22422635.s18.e0" /><pair ddi="false" e1="DDI-PubMed.22422635.s18.e0" e2="DDI-PubMed.22422635.s18.e1" /></sentence><sentence text=" Exposure to midazolam and its 1-hydroxymidazolam metabolite, however, decreased by 27% and increased 4-fold, respectively"><entity charOffset="13-22" id="DDI-PubMed.22422635.s19.e0" text="midazolam" /><entity charOffset="31-49" id="DDI-PubMed.22422635.s19.e1" text="1-hydroxymidazolam" /><pair ddi="false" e1="DDI-PubMed.22422635.s19.e0" e2="DDI-PubMed.22422635.s19.e0" /><pair ddi="false" e1="DDI-PubMed.22422635.s19.e0" e2="DDI-PubMed.22422635.s19.e1" /></sentence><sentence text=" Clobazam increased dextromethorphan (CYP2D6) AUC(0-∞)  by 95% and C(max)  by 59%"><entity charOffset="20-36" id="DDI-PubMed.22422635.s20.e0" text="dextromethorphan" /><entity charOffset="38-44" id="DDI-PubMed.22422635.s20.e1" text="CYP2D6" /><entity charOffset="46-54" id="DDI-PubMed.22422635.s20.e2" text="AUC(0-∞)" /><pair ddi="false" e1="DDI-PubMed.22422635.s20.e0" e2="DDI-PubMed.22422635.s20.e0" /><pair ddi="false" e1="DDI-PubMed.22422635.s20.e0" e2="DDI-PubMed.22422635.s20.e1" /><pair ddi="false" e1="DDI-PubMed.22422635.s20.e0" e2="DDI-PubMed.22422635.s20.e2" /><pair ddi="false" e1="DDI-PubMed.22422635.s20.e1" e2="DDI-PubMed.22422635.s20.e1" /><pair ddi="false" e1="DDI-PubMed.22422635.s20.e1" e2="DDI-PubMed.22422635.s20.e2" /></sentence><sentence text=" In the population pharmacokinetics analysis, stable dosages of common antiepileptic drugs that induce CYP3A4 or CYP2C19, or inhibit CYP2C19, had negligible effects on clobazam or N-CLB"><entity charOffset="168-176" id="DDI-PubMed.22422635.s21.e0" text="clobazam" /><entity charOffset="180-185" id="DDI-PubMed.22422635.s21.e1" text="N-CLB" /><pair ddi="false" e1="DDI-PubMed.22422635.s21.e0" e2="DDI-PubMed.22422635.s21.e0" /><pair ddi="false" e1="DDI-PubMed.22422635.s21.e0" e2="DDI-PubMed.22422635.s21.e1" /></sentence><sentence text=" Clobazam did not affect valproic acid or lamotrigine exposures"><entity charOffset="1-9" id="DDI-PubMed.22422635.s22.e0" text="Clobazam" /><entity charOffset="25-38" id="DDI-PubMed.22422635.s22.e1" text="valproic acid" /><entity charOffset="42-53" id="DDI-PubMed.22422635.s22.e2" text="lamotrigine" /><pair ddi="false" e1="DDI-PubMed.22422635.s22.e0" e2="DDI-PubMed.22422635.s22.e0" /><pair ddi="false" e1="DDI-PubMed.22422635.s22.e0" e2="DDI-PubMed.22422635.s22.e1" /><pair ddi="false" e1="DDI-PubMed.22422635.s22.e0" e2="DDI-PubMed.22422635.s22.e2" /><pair ddi="false" e1="DDI-PubMed.22422635.s22.e1" e2="DDI-PubMed.22422635.s22.e1" /><pair ddi="false" e1="DDI-PubMed.22422635.s22.e1" e2="DDI-PubMed.22422635.s22.e2" /></sentence><sentence text="" /><sentence text="These findings suggest no clinically meaningful drug-drug interactions between clobazam and drugs metabolized by CYP3A4, CYP2C19, CYP1A2, or CYP2C9" /><sentence text=" Concomitant use of drugs metabolized by CYP2D6 may require dosage adjustment" /><sentence text=" Clobazam may be administered safely as adjunctive therapy in patients with Lennox-Gastaut syndrome, without meaningful changes in clobazam pharmacokinetics that would require dosage adjustment"><entity charOffset="1-9" id="DDI-PubMed.22422635.s26.e0" text="Clobazam" /></sentence><sentence text="" /></document>